178 related articles for article (PubMed ID: 34827657)
1. Comparison of Conventional and Radiomic Features between
Liao CY; Jen JH; Chen YW; Li CY; Wang LW; Liu RS; Huang WS; Lu CF
Biomolecules; 2021 Nov; 11(11):. PubMed ID: 34827657
[TBL] [Abstract][Full Text] [Related]
2. Interchangeability of radiomic features between [18F]-FDG PET/CT and [18F]-FDG PET/MR.
Vuong D; Tanadini-Lang S; Huellner MW; Veit-Haibach P; Unkelbach J; Andratschke N; Kraft J; Guckenberger M; Bogowicz M
Med Phys; 2019 Apr; 46(4):1677-1685. PubMed ID: 30714158
[TBL] [Abstract][Full Text] [Related]
3. The impact of ZTE-based MR attenuation correction compared to CT-AC in
Lo YW; Lin KH; Lee CY; Li CW; Lin CY; Chen YW; Wang LW; Wu YH; Huang WS
Sci Rep; 2024 Jun; 14(1):13950. PubMed ID: 38886395
[TBL] [Abstract][Full Text] [Related]
4. 4-Borono-2-
Ishiwata K
Ann Nucl Med; 2019 Apr; 33(4):223-236. PubMed ID: 30820862
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the pharmacokinetics between L-BPA and L-FBPA using the same administration dose and protocol: a validation study for the theranostic approach using [
Watanabe T; Hattori Y; Ohta Y; Ishimura M; Nakagawa Y; Sanada Y; Tanaka H; Fukutani S; Masunaga SI; Hiraoka M; Ono K; Suzuki M; Kirihata M
BMC Cancer; 2016 Nov; 16(1):859. PubMed ID: 27821116
[TBL] [Abstract][Full Text] [Related]
6. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma.
Nariai T; Ishiwata K; Kimura Y; Inaji M; Momose T; Yamamoto T; Matsumura A; Ishii K; Ohno K
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S348-50. PubMed ID: 19375930
[TBL] [Abstract][Full Text] [Related]
7. Similar T/N ratio between
Lin YC; Chou FI; Yang BH; Chang CW; Chen YW; Hwang JJ
Ann Nucl Med; 2020 Jan; 34(1):58-64. PubMed ID: 31650410
[TBL] [Abstract][Full Text] [Related]
8. Quantification of Boron Compound Concentration for BNCT Using Positron Emission Tomography.
Balcerzyk M; De-Miguel M; Guerrero C; Fernandez B
Cells; 2020 Sep; 9(9):. PubMed ID: 32932575
[No Abstract] [Full Text] [Related]
9. Evaluation of 4-borono-2-18F-fluoro-L-phenylalanine-fructose as a probe for boron neutron capture therapy in a glioma-bearing rat model.
Wang HE; Liao AH; Deng WP; Chang PF; Chen JC; Chen FD; Liu RS; Lee JS; Hwang JJ
J Nucl Med; 2004 Feb; 45(2):302-8. PubMed ID: 14960653
[TBL] [Abstract][Full Text] [Related]
10. Development of an Imaging Technique for Boron Neutron Capture Therapy.
Fukumitsu N; Matsumoto Y
Cells; 2021 Aug; 10(8):. PubMed ID: 34440904
[TBL] [Abstract][Full Text] [Related]
11. Assessment of
Shimosegawa E; Isohashi K; Naka S; Horitsugi G; Hatazawa J
Ann Nucl Med; 2016 Dec; 30(10):749-755. PubMed ID: 27586407
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and therapeutic indicator of fluoroboronophenylalanine positron emission tomography in patients with gliomas.
Takahashi Y; Imahori Y; Mineura K
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5888-95. PubMed ID: 14676111
[TBL] [Abstract][Full Text] [Related]
13. On the applicability of [
Grunewald C; Sauberer M; Filip T; Wanek T; Stanek J; Mairinger S; Rollet S; Kudejova P; Langer O; Schütz C; Blaickner M; Kuntner C
Nucl Med Biol; 2017 Jan; 44():83-89. PubMed ID: 27837726
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the image-derived radioactivity and blood-sample radioactivity for estimating the clinical indicators of the efficacy of boron neutron capture therapy (BNCT): 4-borono-2-
Isohashi K; Shimosegawa E; Naka S; Kanai Y; Horitsugi G; Mochida I; Matsunaga K; Watabe T; Kato H; Tatsumi M; Hatazawa J
EJNMMI Res; 2016 Dec; 6(1):75. PubMed ID: 27757932
[TBL] [Abstract][Full Text] [Related]
15. Preliminary feasibility study on differential diagnosis between radiation-induced cerebral necrosis and recurrent brain tumor by means of [
Beshr R; Isohashi K; Watabe T; Naka S; Horitsugi G; Romanov V; Kato H; Miyatake SI; Shimosegawa E; Hatazawa J
Ann Nucl Med; 2018 Dec; 32(10):702-708. PubMed ID: 30194665
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography and [18F]BPA: a perspective application to assess tumour extraction of boron in BNCT.
Menichetti L; Cionini L; Sauerwein WA; Altieri S; Solin O; Minn H; Salvadori PA
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S351-4. PubMed ID: 19410471
[TBL] [Abstract][Full Text] [Related]
17. A multi-modality physical phantom for mimicking tumor heterogeneity patterns in PET/CT and PET/MRI.
Valladares A; Beyer T; Papp L; Salomon E; Rausch I
Med Phys; 2022 Sep; 49(9):5819-5829. PubMed ID: 35838056
[TBL] [Abstract][Full Text] [Related]
18. A Metabolically Stable Boron-Derived Tyrosine Serves as a Theranostic Agent for Positron Emission Tomography Guided Boron Neutron Capture Therapy.
Li J; Shi Y; Zhang Z; Liu H; Lang L; Liu T; Chen X; Liu Z
Bioconjug Chem; 2019 Nov; 30(11):2870-2878. PubMed ID: 31593447
[TBL] [Abstract][Full Text] [Related]
19. Uptake of 4-borono-2-[18F]fluoro-L-phenylalanine in sporadic and neurofibromatosis 2-related schwannoma and meningioma studied with PET.
Havu-Aurén K; Kiiski J; Lehtiö K; Eskola O; Kulvik M; Vuorinen V; Oikonen V; Vähätalo J; Jääskeläinen J; Minn H
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):87-94. PubMed ID: 16896669
[TBL] [Abstract][Full Text] [Related]
20. FBPA PET in boron neutron capture therapy for cancer: prediction of (10)B concentration in the tumor and normal tissue in a rat xenograft model.
Hanaoka K; Watabe T; Naka S; Kanai Y; Ikeda H; Horitsugi G; Kato H; Isohashi K; Shimosegawa E; Hatazawa J
EJNMMI Res; 2014 Dec; 4(1):70. PubMed ID: 25621196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
